According to Israeli researchers, they are likely to cure cancer within one year, according to The Jerusalem Post.
Cancer is an abnormal growth of cells. There are more than 100 types, including skin cancer, lung cancer, breast cancer and colon cancer, and the disease is the second leading cause of death in the United States.
More than half a million people died of cancer in 2015, 1.7% less than in 2014.
This sounds fantastic, especially when 18.1 million new cancers are diagnosed each year worldwide, according to reports from the International Cancer Research Board. One in six cancer worldwide is caused by cancer, making it the second cause of death (the second cause of death after cardiovascular disease).
Aridor, CEO of AEBi and CEO Ilan Morad, explains that their treatment, which they call MuTaTo (multi-target toxin), is essentially the extension of an anti-cancer antibiotic, an advanced technology in the first order.
The multi-measurement toxin treatment developed by an Israeli company has questioned the declared capacity to cure cancer. Ilan Morad, CEO of Codeveloper and the company, recently expressed confidence in an interview with Xinhua.
The anti-cancer drug that can change the game is based on SoAP technology, which is part of the subject-display technology group. DNA encoding a protein, as an antibody, is introduced into a bacteriophage, a virus that infects bacteria. This protein is shown on the surface of the phage. Researchers can use these protein-presenting subjects to look for interactions with other proteins, DNA sequences, and small molecules.
In 2018 a team of researchers won the Nobel Prize for their work in the subject field in the directed development of new proteins, especially for the production of antibody-based drugs.
AEBi works in a similar manner but with peptides composed of two or more amino acids linked in a chain. According to Morad, peptides have several advantages over antibodies, including the fact that they are smaller, cheaper and easier to prepare and regulate.
When the company started, Morad said, “We did exactly the same as everyone else, and we tried to discover new individual peptides for some types of cancer.” Shortly afterwards, Morad and his colleague, Dr. Hanan Itzhaki, wanted to do something bigger.
“We make sure that the treatment is not affected by the mutations and that the cancer cells can mutate for cancer to start specific receptors.”
Morad said the company has so far completed its first experimental experiment in mice that inhibited the growth of human cancer cells and had no effect on cells from healthy mice, as well as several in vitro studies. AEBi should begin a series of clinical trials that may be conducted in a few years, and in some cases it will make the treatment available.
“The probability of having multiple mutations that would modify all the targeted receptors decreases dramatically with the number of targets used,”
“Instead of attacking the receivers one at a time, we attack the receivers three at a time; even cancer cannot mutate three receptors at the same time.”
Aridor said: “Our results are consistent and repeatable.”
It will take several years and a big investment, and there have been many “sleep medications” that do not work as expected when tested in humans, he said.